Break it Down: Recce partners with the US Army
Recce Pharmaceuticals has allied with US Army researchers in a massive R&D deal to advance R327.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
Recce Pharmaceuticals (ASX:RCE)has partnered with the US Army Medical Research Institute of Infectious Diseases in an R&D deal focused on its anti-infective drug R327.
Watch the video to learn more.
While Recce Pharmaceuticals is a Stockhead advertiser, it did not sponsor this content.
Originally published as Break it Down: Recce partners with the US Army
ASX quarterly tech wrap
Decidr AI Industries and Adisyn are among ASX technology companies reporting March quarterly results this week.
ASX health stocks give March quarter progress
Island Pharmaeuticals, Dimerix and Tryptamine Therapeutics are among ASX health stocks reporting quarterly results this week.